Minerva Neurosciences Investor Relations Material
Latest events
Q1 2023
Minerva Neurosciences
Q2 2025
14 Aug, 2025
Q1 2025
12 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Minerva Neurosciences Inc
Access all reports
Minerva Neurosciences Inc is a biopharmaceutical company focused on the development of therapies for central nervous system disorders. The company's research targets conditions such as schizophrenia, depression, and insomnia through proprietary drug candidates. Minerva Neurosciences collaborates with academic and industry partners to advance its clinical programs. The company is headquartered in Burlington, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
NERV
Country
🇺🇸 United States